The shareholders in NeoDynamics have been conveyed to the annual general meeting on Tuesday 23 May 2023 at 15.00 at the Company’s premises at Lejonvägen 14, Lidingö.
As of the date of this notice, there is a total of 120,501,184 shares and votes in the Company.
If any shareholder requests it and the board of directors determines that doing so can be accomplished without causing the company significant damage, the board of directors and the CEO shall provide information at the annual general meeting on matters that may affect the assessment of a matter on the agenda and the Company's financial situation.
Read the whole announcement here: https://www.neodynamics.com/sv-se/tools/GetCisionNews?id=4523307&lang=eng
Neodynamics
NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden.
Read more on company page